All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
During the EHA2021 Virtual Congress, the MPN Hub spoke with Haifa Kathrin Al-Ali, University Hospital Halle (Saale), Halle, DE. We asked, How do patients with myelofibrosis (MF) and lower grade fibrosis benefit from ruxolitinib?
JUMP trial: How do patients with MF and lower grade fibrosis benefit from ruxolitinib?
In this video, Al-Ali discusses insights from the JUMP trial, evaluating the impact of ruxolitinib on low-grade bone marrow fibrosis. She touches upon the degree of fibrosis, time to diagnosis, survival and long-term outcomes, prognostic factors, and response rates.
Novel agents to treat MF with suboptimal response to ruxolitinib: Combining ruxolitinib with navitoclax or KRT-232
Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway dysregulation is central to the pathogenesis of...
When would you switch a patient with myelofibrosis from ruxolitinib?
During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Haifa Kathrin Al-Ali, University Hospital Halle (Saale), Halle, DE. We asked, When would you switch a patient...
Subscribe to get the best content related to MPN delivered to your inbox